Quesnel, Bruno

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 475

Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I., Peterlin, P., Bève, B., Attalah, H., Chermat, F., et al. (2021) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 279

Tumor dormancy and immunoescape

QUESNEL, B. (2008) · APMIS

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 90

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 26

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML:GFM's “pick a winner” trial, with the impact of somatic mutations

Adès, L., Duployez, N., Guerci‐Bresler, A., Laribi, K., Peterlin, P., Vey, N., Thepot, S., Wickenhauser, S., Zerazhi, H., Stamatoullas, A., et al. (2022) · British Journal of Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 21